New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review

Gheorghe, Adelina Silvana; Dumitrescu, Elena Adriana; Komporaly, Isabela Anda; Mihăilă, Raluca Ioana; Lungulescu, Cristian Virgil; Stănculeanu, Dana Lucia

doi:10.3390/curroncol29040231

Cited by 9 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of camrelizumab and apatinib with fuzuloparib can be used in other types of cancers as well after its propitious results in treating platinum-resistant ovarian cancer 18 . The combination therapy of camrelizumab plus apatinib and paclitaxel is also used in cervical cancer 19 .…”

Section: Usage In Other Cancersmentioning

confidence: 99%

PDL-1, PARP, and VEGFR inhibition: A potential combination regimen for targeting triple-negative breast cancer?

Abdul Wahid,

Hussain,

Ghouri

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

Section: Usage In Other Cancersmentioning

confidence: 99%

PDL-1, PARP, and VEGFR inhibition: A potential combination regimen for targeting triple-negative breast cancer?

Abdul Wahid,

Hussain,

Ghouri

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

“… 1 Historically, UCEC displayed a favorable prognosis, characterized by elevated cure rates and an overall 5-year survival rate ranging between 75% and 80% following surgical intervention. 2 Despite numerous attempts to improve post-operative prognosis, chemoresistance remains a challenge, especially for patients at advanced stages. 3 , 4 Furthermore, over the past 40 years, the incidence of UCEC has doubled, which has been attributed to high-risk factors such as obesity, diabetes, estrogen use and polycystic ovary syndrome.…”

Section: Introductionmentioning

confidence: 99%

SIM2: Its Prognostic Significance and Oncogenic Role in Endometrial Carcinoma

Wei,

Zhao,

Tang

et al. 2024

OTT

View full text Add to dashboard Cite

Background Endometrial carcinoma ranks as the second most widespread malignancy affecting the reproductive system in females. Effective prognostic biomarkers are required to further improve survival rates for patients. Single-minded homolog 2 (SIM2) is known to participate in neurogenesis as a transcription factor. However, the potential role of SIM2 in endometrial carcinoma remains elusive. Methods Multiple public databases, including TIMER2.0, GEIPA2, UALCAN, LinkedOmics, BioGRID, DAVID and cBioPortal, were used to investigate SIM2 mRNA expression, SIM2-associated genes, PPI network, functional enrichment analysis, SIM2 gene alterations and methylation. The association between SIM2 expression and immune cell infiltrates was explored using GSVA. The effects of gene alterations and methylation on patient survival and CD8+T infiltration were examined using GSCA. Moreover, the prognostic potential of SIM2 was evaluated using COX regression, ROC curves and a nomogram model. Finally, the differential expression and function of SIM2 in UCEC were explored using qPCR, WB, CCK8 and Transwell assays. Results Our findings revealed the heightened expression of SIM2 in endometrial carcinoma, and that its DNA methylation and CNV alterations were correlated with immune infiltration and patients’ prognosis. Additionally, functional enrichment revealed the involvement of SIM2 in transcription regulation and signal transduction. Moreover, we performed cell-based experiments to corroborate the oncogenic function of SIM2 in facilitating cell proliferation, migration and invasion. Conclusion Collectively, these results suggest that SIM2 holds promise as both a potential prognostic indicator and a viable treatment target for endometrial carcinoma.

show abstract

“…Although many women achieve remission with standard treatment, the recurrence of cancer and resistance to chemo-therapeutics pose significant challenges for the majority of OC patients [4,5]. Thus, novel therapies, including targeted therapy, are in high demand for the treatment of OC, especially for those patients who have relapsed [6,7].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Huang

Fan

Zhao

et al. 2023

IJMS

View full text Add to dashboard Cite

Ovarian cancer is the deadliest gynecological malignancy of the reproductive organs in the United States. Cyclin-dependent kinase 1 (CDK1) is an important cell cycle regulatory protein that specifically controls the G2/M phase transition of the cell cycle. RO-3306 is a selective, ATP-competitive, and cell-permeable CDK1 inhibitor that shows potent anti-tumor activity in multiple pre-clinical models. In this study, we investigated the effect of CDK1 expression on the prognosis of patients with ovarian cancer and the anti-tumorigenic effect of RO-3306 in both ovarian cancer cell lines and a genetically engineered mouse model of high-grade serous ovarian cancer (KpB model). In 147 patients with epithelial ovarian cancer, the overexpression of CDK1 was significantly associated with poor prognosis compared with a low expression group. RO-3306 significantly inhibited cellular proliferation, induced apoptosis, caused cellular stress, and reduced cell migration. The treatment of KpB mice with RO-3306 for four weeks showed a significant decrease in tumor weight under obese and lean conditions without obvious side effects. Overall, our results demonstrate that the inhibition of CDK1 activity by RO-3306 effectively reduces cell proliferation and tumor growth, providing biological evidence for future clinical trials of CDK1 inhibitors in ovarian cancer.

show abstract

New Targeted Therapies and Combinations of Treatments for Cervical, Endometrial, and Ovarian Cancers: A Year in Review

Cited by 9 publications

References 59 publications

PDL-1, PARP, and VEGFR inhibition: A potential combination regimen for targeting triple-negative breast cancer?

PDL-1, PARP, and VEGFR inhibition: A potential combination regimen for targeting triple-negative breast cancer?

SIM2: Its Prognostic Significance and Oncogenic Role in Endometrial Carcinoma

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer

Contact Info

Product

Resources

About